Cetuxim IV Infusion

Introduction

Cetuxim IV Infusion 5 mg/ml is a monoclonal antibody used in the treatment of certain types of cancer. It specifically targets and inhibits the epidermal growth factor receptor (EGFR), which plays a critical role in the growth and spread of cancer cells. Cetuxim IV Infusion 5 mg/ml is used primarily for treating head and neck cancers and colorectal cancer.

Uses

Cetuxim IV Infusion 5 mg/ml is used for:

Metastatic colorectal cancer (mCRC) in combination with chemotherapy, particularly in patients with EGFR-expressing tumors.
Locally advanced squamous cell carcinoma of the head and neck (SCCHN) in combination with radiation therapy.
Recurrent or metastatic head and neck cancer, either alone or in combination with other therapies.

The drug is typically used when other treatments have been ineffective or are not appropriate.

Brand Name	Cetuxim
Type	IV Infusion
Weight	5 mg/ml
Generic	Cetuximab
Manufacturer	Beacon Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Cetuxim IV Infusion 5 mg/ml works by binding to the extracellular domain of the EGFR. This binding blocks the receptor's activation by its natural ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha). This inhibition prevents the activation of downstream signaling pathways that promote cell proliferation, survival, and angiogenesis, leading to reduced tumor growth and spread.

How Long Does It Take to Work?

The clinical effects of Cetuxim IV Infusion 5 mg/ml may be observed after a few weeks of treatment, although the exact time can vary depending on the type and stage of cancer being treated. Response to treatment should be monitored by a healthcare provider through regular imaging and clinical assessments.

Absorption

Cetuxim IV Infusion 5 mg/ml is administered intravenously (IV), and therefore, systemic absorption is not a factor. Once infused, it is distributed throughout the bloodstream and tissues where it exerts its therapeutic effects.

Route of Elimination

Cetuxim IV Infusion 5 mg/ml is primarily eliminated through catabolism in the liver and other tissues. It is broken down into smaller peptides and amino acids, which are then excreted via the urinary and fecal routes. The exact elimination pathways are not fully detailed but involve protein metabolism processes.

Dosage

Squamous Cell Carcinoma Of The Head And Neck:

Cetuximab in combination with radiation therapy or in combination with platinum-based therapy with 5-FU:

The recommended initial dose is 400 mg/m² administered one week prior to initiation of a course of radiation therapy or on the day of initiation of platinum-based therapy with 5-FU as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min). Complete Cetuximab administration 1 hour prior to platinum-based therapy with 5-FU.
The recommended subsequent weekly dose (all other infusions) is 250 mg/m² infused over 60 minutes (maximum infusion rate 10 mg/min) for the duration of radiation therapy (6–7 weeks) or until disease progression or unacceptable toxicity when administered in combination with platinum-based therapy with 5-FU. Complete Cetuximab administration 1 hour prior to radiation therapy or platinumbased therapy with 5-FU.

Cetuximab monotherapy:

The recommended initial dose is 400 mg/m² administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min).
The recommended subsequent weekly dose (all other infusions) is 250 mg/m² infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity.

Colorectal Cancer:

Determine EGFR-expression status using FDA-approved tests prior to initiating treatment. Also confirm the absence of a Ras mutation prior to initiation of treatment with Cetuximab.
The recommended initial dose, either as monotherapy or in combination with irinotecan or FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), is 400 mg/m² administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min). Complete Cetuximab administration 1 hour prior to FOLFIRI.
The recommended subsequent weekly dose, either as monotherapy or in combination with irinotecan or FOLFIRI, is 250 mg/m² infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Complete Cetuximab administration 1 hour prior to FOLFIRI.

Recommended Premedication: Premedicate with an H1 antagonist (eg, 50 mg of diphenhydramine) intravenously 30–60 minutes prior to the first dose; premedication should be administered for subsequent Cetuximab doses based upon clinical judgment and presence/severity of prior infusion reactions.

The typical dosing regimen for Cetuxim IV Infusion 5 mg/ml is:

A loading dose of 400 mg/m² administered intravenously over 120 minutes.
Subsequent weekly doses of 250 mg/m² administered intravenously over 60 minutes.

Dosing may be adjusted based on patient response, tolerance, and specific clinical guidelines. The dose and schedule may vary based on the type of cancer and treatment regimen used.

Administration

Cetuxim IV Infusion 5 mg/ml is administered via intravenous infusion. The initial infusion should be given slowly over 120 minutes to minimize the risk of infusion-related reactions. Subsequent infusions are typically administered over 60 minutes. The infusion rate may be adjusted based on tolerance and adverse reactions.

Side Effects

Common side effects include:

Skin rash and acneiform dermatitis.
Diarrhea.
Nausea and vomiting.
Infusion-related reactions such as fever, chills, and hypotension.
Fatigue.

Serious side effects can include severe allergic reactions, pulmonary embolism, and liver toxicity. Regular monitoring is essential to manage side effects effectively.

Toxicity

Potential toxic effects of Cetuxim IV Infusion 5 mg/ml include:

Severe skin reactions such as exfoliative dermatitis or severe acneiform rash.
Gastrointestinal issues such as severe diarrhea.
Potential for infusion-related reactions, including anaphylaxis.

Immediate medical attention should be sought if severe symptoms or allergic reactions occur.

Precautions

Precautions include:

Monitoring for and managing infusion-related reactions.
Assessing and managing potential skin reactions and gastrointestinal symptoms.
Pre-treatment screening for EGFR expression to ensure the drug's appropriateness for the patient’s cancer type.

Regular monitoring and supportive care are essential to mitigate potential side effects.

Interaction

Cetuxim IV Infusion 5 mg/ml may interact with:

Cytotoxic agents and other chemotherapeutic drugs, potentially increasing the risk of adverse effects.
Medications that can affect liver metabolism and clearance.

Inform your healthcare provider of all medications and supplements you are taking to avoid interactions.

Disease Interaction

Cetuxim IV Infusion 5 mg/ml should be used with caution in patients with:

Pre-existing skin disorders or conditions that may exacerbate rash or skin reactions.
Liver impairment, as it may affect drug metabolism and increase the risk of side effects.

Regular monitoring and evaluation are necessary to manage these conditions effectively.

Drug Interaction

Drug interactions may occur with:

Other drugs that affect the metabolism or clearance of Cetuxim IV Infusion 5 mg/ml.
Drugs that can increase the risk of severe side effects or adverse reactions.

Always discuss all medications with your healthcare provider to manage potential interactions.

Food Interactions

There are no specific food interactions with Cetuxim IV Infusion 5 mg/ml. However, maintaining a balanced diet and avoiding significant dietary changes during treatment is advisable to support overall health and well-being.

Pregnancy Use

Cetuxim IV Infusion 5 mg/ml is classified as a Category C drug for pregnancy. It is not recommended for use during pregnancy due to potential risks to the developing fetus. Adequate contraception should be used to prevent pregnancy during treatment.

Lactation Use

It is not known if Cetuxim IV Infusion 5 mg/ml is excreted in breast milk. Due to potential risks to the infant, it is generally recommended to avoid breastfeeding during treatment and for some time after the last dose. Consult your healthcare provider for specific recommendations.

Acute Overdose

Acute overdose may result in exacerbated side effects such as severe skin reactions, gastrointestinal symptoms, or infusion-related reactions. In case of overdose, seek immediate medical attention. Management will involve supportive care and symptomatic treatment.

Contraindication

Cetuxim IV Infusion 5 mg/ml is contraindicated in:

Pregnancy due to potential harm to the fetus.
Patients with severe hypersensitivity reactions to Cetuxim IV Infusion 5 mg/ml or other components of the formulation.

Ensure to discuss your medical history and any potential contraindications with your healthcare provider before starting treatment.

Use Direction

Follow the prescribed dosing regimen and administration schedule. Cetuxim IV Infusion 5 mg/ml should be administered by a healthcare professional trained in the use of intravenous chemotherapy agents. Report any side effects or symptoms immediately for appropriate management.

Storage Conditions

Store Cetuxim IV Infusion 5 mg/ml vials in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep the vials in their original packaging until use. Discard any unused or expired medication appropriately.

Volume of Distribution

The volume of distribution for Cetuxim IV Infusion 5 mg/ml is not explicitly specified, but it is distributed widely throughout the body after intravenous administration, targeting tissues where EGFR is expressed.

Half Life

The terminal half-life of Cetuxim IV Infusion 5 mg/ml is approximately 5 to 9 days. This half-life supports its dosing schedule, which typically involves weekly administration to maintain effective drug levels.

Clearance

Cetuxim IV Infusion 5 mg/ml is cleared primarily through catabolism in the liver and other tissues. The clearance rate can be affected by factors such as liver function and other medications. Monitoring and dosage adjustments may be necessary based on individual patient factors.

See in details version Cetuxim IV Infusion 5 mg/ml also Cetuxim IV Infusion 5 mg/ml in bangla